The global rehabilitation robots market was valued at USD 1.18 billion in 2025. It is estimated at USD 1.36 billion in 2026 and is projected to reach USD 6.82 billion by 2036, growing at a CAGR of 17.5% over the 2026-2036 forecast period. The report examines epidemiology and unmet need, clinical evidence, device technology, regulation and reimbursement, pricing, the value chain, the competitive landscape, and the main growth opportunities for device makers through 2036.
The study covers robotic and powered devices that help people with neurological, musculoskeletal, and age-related impairments regain, support, or practice movement. Included are treadmill-based and end-effector gait trainers used in clinics, lower-limb exoskeletons for clinical therapy and personal mobility, arm and shoulder therapy robots, powered wearable orthoses that strengthen faint muscle signals, hand and finger devices, anti-gravity, body-weight support, and balance systems, plus the software, tele-rehabilitation tools, and services that go with them. Exoskeletons built for industrial workers, prosthetic limbs, and surgical robots are not part of the scope. Buyers and influencers include rehabilitation hospitals and clinics, therapists, payers including Medicare, national insurers, and the U.S. Department of Veterans Affairs, as well as regulators, patients, and caregivers.
According to the World Stroke Organization, roughly 12 million strokes occur each year and over 100 million people live with their after-effects, creating a large and growing patient pool, while the World Health Organization (WHO) puts the number of people living with spinal cord injury above 15 million and expects one in six people worldwide to be 60 or older by 2030. Payment for personal devices is also improving: the U.S. Centers for Medicare & Medicaid Services (CMS) finalized in April 2024 a single Medicare payment of USD 91,032 per personal exoskeleton, and Myomo reported that fourth-quarter 2024 revenue climbed 154% to USD 12.1 million as it began serving Medicare Part B patients with its MyoPro arm orthosis.
Growth is held back by high device prices and patchy reimbursement, since clinical systems need large capital budgets and private insurers often decide personal device coverage one case at a time. Evidence is uneven across uses; the RATULS trial, which enrolled 770 stroke patients and appeared in The Lancet in 2019, showed that robot-assisted arm training did no better than usual care, although a Cochrane review supports electromechanical gait training. Many suppliers are small firms with thin finances, and devices are cleared only for set conditions and body limits, which narrows the pool of eligible users. The market also faces a shortage of trained therapists, strict regulatory demands for devices used at home, the cost of proving long-term outcomes and value to payers, and differing coverage rules from country to country.
Personal exoskeletons for use at home and in the community, wearable orthoses that restore arm function in daily life, and connected tele-rehabilitation that lets each therapist oversee more patients offer the largest opportunities. Key trends include the move of therapy from clinics into homes, self-balancing exoskeletons that free the user's hands, the use of sensors, data, and AI to tailor assistance, and the transfer of humanoid robotics advances into rehabilitation devices; Fourier Intelligence, which started in rehabilitation robotics, built the GR-1 humanoid that NVIDIA used to show its GR00T N1 foundation model in March 2025.
By product, the market covers gait training robots (treadmill-based and end-effector systems), lower-limb exoskeletons (clinical and personal), upper-limb rehabilitation robots, wearable powered orthoses, hand & finger rehabilitation robots, body-weight support & balance systems, and software & tele-rehabilitation. Gait training robots are expected to hold the largest share in 2026, reflecting a large installed base in rehabilitation hospitals, well-established clinical protocols, and supportive evidence that robot-assisted walking practice improves independence after stroke. Wearable powered orthoses are expected to grow at the highest CAGR, as Medicare coverage has opened a payment route and patients want devices that help with everyday tasks at home rather than only during clinic sessions. Personal exoskeletons are another fast-rising category, helped by the new Medicare payment and rising ReWalk deliveries.
By body part, the study covers lower extremity, upper extremity, and full body devices. Lower extremity devices are expected to account for the largest share in 2026, because regaining the ability to walk is a primary goal of rehabilitation and hospitals have invested widely in gait trainers and exoskeletons. Upper extremity devices are expected to grow at the highest CAGR, supported by new reimbursement for wearable arm orthoses and the very large number of stroke survivors who live with lasting arm and hand weakness. Full body systems address a smaller group of patients with complex needs.
By care setting, the market is divided into clinical and home & personal use. The clinical setting is expected to hold the larger share in 2026, as hospitals and rehabilitation centers remain the main buyers of gait trainers and upper-limb systems and provide the supervised therapy most patients receive after an injury. Home & personal use is expected to grow at the higher CAGR, driven by the April 2024 Medicare payment for personal exoskeletons, wider coverage of powered orthoses, and the benefit of continuing therapy after discharge. This shift is gradually moving the customer base from institutions to individual patients.
By indication, the report covers stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy, and orthopedic & geriatric conditions. Stroke is expected to represent the largest share in 2026, given the size of the survivor population, the frequency of long-term limb weakness, and the strength of evidence for robotic gait training in this group. Orthopedic & geriatric conditions are expected to grow at the highest CAGR, as populations age and older adults seek help with mobility and balance after falls, fractures, and joint surgery. Spinal cord injury remains a key indication for exoskeletons and is the focus of most personal device clearances.
By end user, the study covers hospitals & rehabilitation centers, outpatient & physical therapy clinics, home care & personal users, military & veterans healthcare, and research institutions. Hospitals & rehabilitation centers are expected to account for the largest share in 2026, as they handle acute and inpatient neurological rehabilitation, have the staff to run robotic programs, and can fund capital equipment. Home care & personal users are expected to grow at the highest CAGR, supported by reimbursement for personal devices and the move of rehabilitation into the community. Military & veterans healthcare is an important early adopter, backed by the Veterans Health Administration's long-standing exoskeleton policy.
North America is expected to remain the biggest regional market in 2026 because the United States benefits from the new Medicare payment for personal exoskeletons, a Veterans Health Administration policy that covers about 9 million veterans, a broad network of rehabilitation hospitals, and leading suppliers such as Ekso Bionics, Myomo, and Lifeward, which operates from the U.S. and Israel. FDA clearances such as that of the self-balancing Atalante X further support adoption, and rehabilitation hospitals in Canada are also adding robotic therapy.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by fast-aging populations, rising stroke cases, and strong local robotics industries. Japan is home to Cyberdyne, whose HAL exoskeleton gained national health insurance coverage for certain neuromuscular diseases, and to Toyota, which developed the Welwalk gait trainer, while China's Fourier Intelligence and other domestic makers are scaling output and South Korea's Angel Robotics adds to regional supply, with India and Australia also contributing. Europe holds a significant share and hosts major manufacturers, including Switzerland's Hocoma, maker of the Lokomat, Austria's Tyromotion, and France's Wandercraft; within the region, DGUV coverage makes Germany a key market, while EU Medical Device Regulation deadlines in 2027 and 2028 add compliance costs. Brazil and Mexico lead Latin America, where adoption centers on major rehabilitation hospitals, and in the Middle East & Africa, Israel is a hub of innovation as the home of ReWalk, while Saudi Arabia and the UAE invest in advanced rehabilitation centers.
The market is fragmented, with specialist rehabilitation robotics firms, medical technology groups, Japanese and Chinese robotics companies, and young companies building exoskeletons, gait trainers, arm robots, and wearable orthoses. Vendors compete on clinical evidence, regulatory clearances, reimbursement, device weight and ease of use, therapist workflow, software and data, service and training, and price. Leading players are pursuing payer coverage, entering home and personal use, building self-balancing and lighter devices, adding tele-rehabilitation software, and combining portfolios, as Lifeward did by pairing ReWalk exoskeletons with AlterG anti-gravity systems. Notable recent milestones include the FDA's go-ahead for Atalante X and Medicare's decision on exoskeleton payment, both in 2024.
Key companies profiled in the report include DIH Holding US, Inc. (Hocoma, Motek) (Switzerland/U.S.), Lifeward Ltd. (ReWalk, AlterG) (U.S./Israel), Ekso Bionics Holdings, Inc. (U.S.), Myomo, Inc. (U.S.), Wandercraft SAS (France), Tyromotion GmbH (Austria), Bionik Laboratories Corp. (U.S.), Motorika (Israel), Harmonic Bionics, Inc. (U.S.), Barrett Medical (U.S.), Cyberdyne Inc. (Japan), Toyota Motor Corporation (Japan), Fourier Intelligence (China), and Angel Robotics Co., Ltd. (South Korea).
The study covers robotic and powered devices that help people with neurological, musculoskeletal, and age-related impairments regain, support, or practice movement. Included are treadmill-based and end-effector gait trainers used in clinics, lower-limb exoskeletons for clinical therapy and personal mobility, arm and shoulder therapy robots, powered wearable orthoses that strengthen faint muscle signals, hand and finger devices, anti-gravity, body-weight support, and balance systems, plus the software, tele-rehabilitation tools, and services that go with them. Exoskeletons built for industrial workers, prosthetic limbs, and surgical robots are not part of the scope. Buyers and influencers include rehabilitation hospitals and clinics, therapists, payers including Medicare, national insurers, and the U.S. Department of Veterans Affairs, as well as regulators, patients, and caregivers.
According to the World Stroke Organization, roughly 12 million strokes occur each year and over 100 million people live with their after-effects, creating a large and growing patient pool, while the World Health Organization (WHO) puts the number of people living with spinal cord injury above 15 million and expects one in six people worldwide to be 60 or older by 2030. Payment for personal devices is also improving: the U.S. Centers for Medicare & Medicaid Services (CMS) finalized in April 2024 a single Medicare payment of USD 91,032 per personal exoskeleton, and Myomo reported that fourth-quarter 2024 revenue climbed 154% to USD 12.1 million as it began serving Medicare Part B patients with its MyoPro arm orthosis.
Market Dynamics
Rising numbers of stroke survivors, people with spinal cord injury, and older adults with limited mobility are the main source of demand, and the WHO estimates that about 2.4 billion people have a condition that rehabilitation could help. Robots let therapists give more intensive, repetitive, and measurable training, which is linked to better recovery, at a time when the need for therapy outpaces health system capacity. New coverage is a second driver: Medicare now pays for personal exoskeletons, the Veterans Health Administration has covered them under a dedicated policy since 2015, and Germany's statutory accident insurer DGUV has covered these devices since 2019. Technical progress adds further momentum, as seen in the February 2024 FDA clearance of Atalante X, Wandercraft's exoskeleton that balances on its own, and in lighter actuators, better batteries, and sensors that adjust assistance in real time.Growth is held back by high device prices and patchy reimbursement, since clinical systems need large capital budgets and private insurers often decide personal device coverage one case at a time. Evidence is uneven across uses; the RATULS trial, which enrolled 770 stroke patients and appeared in The Lancet in 2019, showed that robot-assisted arm training did no better than usual care, although a Cochrane review supports electromechanical gait training. Many suppliers are small firms with thin finances, and devices are cleared only for set conditions and body limits, which narrows the pool of eligible users. The market also faces a shortage of trained therapists, strict regulatory demands for devices used at home, the cost of proving long-term outcomes and value to payers, and differing coverage rules from country to country.
Personal exoskeletons for use at home and in the community, wearable orthoses that restore arm function in daily life, and connected tele-rehabilitation that lets each therapist oversee more patients offer the largest opportunities. Key trends include the move of therapy from clinics into homes, self-balancing exoskeletons that free the user's hands, the use of sensors, data, and AI to tailor assistance, and the transfer of humanoid robotics advances into rehabilitation devices; Fourier Intelligence, which started in rehabilitation robotics, built the GR-1 humanoid that NVIDIA used to show its GR00T N1 foundation model in March 2025.
Segment Analysis
The report analyzes the market by product, body part, care setting, indication, end user, and geography, helping stakeholders identify the most attractive areas for investment and growth.By product, the market covers gait training robots (treadmill-based and end-effector systems), lower-limb exoskeletons (clinical and personal), upper-limb rehabilitation robots, wearable powered orthoses, hand & finger rehabilitation robots, body-weight support & balance systems, and software & tele-rehabilitation. Gait training robots are expected to hold the largest share in 2026, reflecting a large installed base in rehabilitation hospitals, well-established clinical protocols, and supportive evidence that robot-assisted walking practice improves independence after stroke. Wearable powered orthoses are expected to grow at the highest CAGR, as Medicare coverage has opened a payment route and patients want devices that help with everyday tasks at home rather than only during clinic sessions. Personal exoskeletons are another fast-rising category, helped by the new Medicare payment and rising ReWalk deliveries.
By body part, the study covers lower extremity, upper extremity, and full body devices. Lower extremity devices are expected to account for the largest share in 2026, because regaining the ability to walk is a primary goal of rehabilitation and hospitals have invested widely in gait trainers and exoskeletons. Upper extremity devices are expected to grow at the highest CAGR, supported by new reimbursement for wearable arm orthoses and the very large number of stroke survivors who live with lasting arm and hand weakness. Full body systems address a smaller group of patients with complex needs.
By care setting, the market is divided into clinical and home & personal use. The clinical setting is expected to hold the larger share in 2026, as hospitals and rehabilitation centers remain the main buyers of gait trainers and upper-limb systems and provide the supervised therapy most patients receive after an injury. Home & personal use is expected to grow at the higher CAGR, driven by the April 2024 Medicare payment for personal exoskeletons, wider coverage of powered orthoses, and the benefit of continuing therapy after discharge. This shift is gradually moving the customer base from institutions to individual patients.
By indication, the report covers stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, cerebral palsy, and orthopedic & geriatric conditions. Stroke is expected to represent the largest share in 2026, given the size of the survivor population, the frequency of long-term limb weakness, and the strength of evidence for robotic gait training in this group. Orthopedic & geriatric conditions are expected to grow at the highest CAGR, as populations age and older adults seek help with mobility and balance after falls, fractures, and joint surgery. Spinal cord injury remains a key indication for exoskeletons and is the focus of most personal device clearances.
By end user, the study covers hospitals & rehabilitation centers, outpatient & physical therapy clinics, home care & personal users, military & veterans healthcare, and research institutions. Hospitals & rehabilitation centers are expected to account for the largest share in 2026, as they handle acute and inpatient neurological rehabilitation, have the staff to run robotic programs, and can fund capital equipment. Home care & personal users are expected to grow at the highest CAGR, supported by reimbursement for personal devices and the move of rehabilitation into the community. Military & veterans healthcare is an important early adopter, backed by the Veterans Health Administration's long-standing exoskeleton policy.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 19 countries and five rest-of-region groups. The regional analysis considers disease burden and aging, reimbursement and regulation, rehabilitation infrastructure, and the presence of device makers.North America is expected to remain the biggest regional market in 2026 because the United States benefits from the new Medicare payment for personal exoskeletons, a Veterans Health Administration policy that covers about 9 million veterans, a broad network of rehabilitation hospitals, and leading suppliers such as Ekso Bionics, Myomo, and Lifeward, which operates from the U.S. and Israel. FDA clearances such as that of the self-balancing Atalante X further support adoption, and rehabilitation hospitals in Canada are also adding robotic therapy.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, supported by fast-aging populations, rising stroke cases, and strong local robotics industries. Japan is home to Cyberdyne, whose HAL exoskeleton gained national health insurance coverage for certain neuromuscular diseases, and to Toyota, which developed the Welwalk gait trainer, while China's Fourier Intelligence and other domestic makers are scaling output and South Korea's Angel Robotics adds to regional supply, with India and Australia also contributing. Europe holds a significant share and hosts major manufacturers, including Switzerland's Hocoma, maker of the Lokomat, Austria's Tyromotion, and France's Wandercraft; within the region, DGUV coverage makes Germany a key market, while EU Medical Device Regulation deadlines in 2027 and 2028 add compliance costs. Brazil and Mexico lead Latin America, where adoption centers on major rehabilitation hospitals, and in the Middle East & Africa, Israel is a hub of innovation as the home of ReWalk, while Saudi Arabia and the UAE invest in advanced rehabilitation centers.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, a competitive dashboard that classifies vendors as industry leaders, market differentiators, vanguards, and emerging companies, and a 2025 market share/rank analysis. Company profiles cover business overview, financial performance, product portfolio, strategic developments, and SWOT analysis.The market is fragmented, with specialist rehabilitation robotics firms, medical technology groups, Japanese and Chinese robotics companies, and young companies building exoskeletons, gait trainers, arm robots, and wearable orthoses. Vendors compete on clinical evidence, regulatory clearances, reimbursement, device weight and ease of use, therapist workflow, software and data, service and training, and price. Leading players are pursuing payer coverage, entering home and personal use, building self-balancing and lighter devices, adding tele-rehabilitation software, and combining portfolios, as Lifeward did by pairing ReWalk exoskeletons with AlterG anti-gravity systems. Notable recent milestones include the FDA's go-ahead for Atalante X and Medicare's decision on exoskeleton payment, both in 2024.
Key companies profiled in the report include DIH Holding US, Inc. (Hocoma, Motek) (Switzerland/U.S.), Lifeward Ltd. (ReWalk, AlterG) (U.S./Israel), Ekso Bionics Holdings, Inc. (U.S.), Myomo, Inc. (U.S.), Wandercraft SAS (France), Tyromotion GmbH (Austria), Bionik Laboratories Corp. (U.S.), Motorika (Israel), Harmonic Bionics, Inc. (U.S.), Barrett Medical (U.S.), Cyberdyne Inc. (Japan), Toyota Motor Corporation (Japan), Fourier Intelligence (China), and Angel Robotics Co., Ltd. (South Korea).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global rehabilitation robots market through 2036.
- Explains how stroke, spinal cord injury, and population aging are expanding the need for robotic rehabilitation.
- Assesses the impact of Medicare, Veterans Health Administration, and German statutory coverage on personal device adoption.
- Reviews clinical evidence for gait training, upper-limb robotics, and personal exoskeletons, and its effect on purchasing and payment.
- Identifies high-growth opportunities across product, body part, care setting, indication, end user, and region.
- Tracks technologies such as self-balancing exoskeletons, EMG-driven orthoses, AI-based adaptive assistance, and tele-rehabilitation.
- Supports product planning, reimbursement strategy, market entry, and investment decisions for device makers, providers, payers, and investors.
Key Questions Answered
- How large is the global rehabilitation robots market today, and how fast will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How will Medicare payment for personal exoskeletons change demand for home and personal devices?
- Which applications have strong clinical evidence, and where does evidence remain mixed?
- Which product, body part, care setting, indication, and end user segments will grow the fastest?
- How are self-balancing designs, AI, and humanoid robotics advances changing device capabilities?
- Which regions and countries offer the most attractive opportunities for manufacturers?
- Who are the leading companies in the market, and how do they compare?
- What clearances, coverage decisions, and portfolio moves are shaping competition?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Rehabilitation Robots Market, by Product
6. Rehabilitation Robots Market, by Body Part
7. Rehabilitation Robots Market, by Care Setting
8. Rehabilitation Robots Market, by Indication
9. Rehabilitation Robots Market, by End User
10. Rehabilitation Robots Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- DIH Holding US, Inc.
- Lifeward Ltd.
- Ekso Bionics Holdings, Inc.
- Myomo, Inc.
- Wandercraft SAS
- Tyromotion GmbH
- Bionik Laboratories Corp.
- Motorika
- Harmonic Bionics, Inc.
- Barrett Medical
- Cyberdyne Inc.
- Toyota Motor Corporation
- Fourier Intelligence
- Angel Robotics Co., Ltd.
